Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
about
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazoneThe fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activitiesMacrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid.A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.Fluorescent high-content imaging allows the discrimination and quantitation of E-LDL-induced lipid droplets and Ox-LDL-generated phospholipidosis in human macrophages.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligandControl of macrophage activation and function by PPARs.15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.Animal models of ischemic stroke. Part one: modeling risk factors.Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harmThiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting.Peroxisome proliferator-activated receptors.Peroxisome proliferator-activated receptor gamma and atherosclerosis.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.Orphan nuclear receptors find a home in the arterial wall.Animal models of cardiovascular diseasesVascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies.Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in miceInsulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophagesPeroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.The Role of PPARgamma in pulmonary vascular diseaseThe role of peroxisome proliferator-activated receptors in pulmonary vascular disease.Peroxisome proliferator-activated receptor ligands in atherosclerosis.Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.Peroxisome proliferator-activated receptor gamma: the more the merrier?Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.The inflammation highway: metabolism accelerates inflammatory traffic in obesity.Roles for lipid-activated transcription factors in atherosclerosis.Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.Combinatorial roles of nuclear receptors in inflammation and immunity.The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosisTranscriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.
P2860
Q28512042-C3364DA0-794F-46FD-84DA-3931DD41388EQ28513582-91F29E23-2245-4352-ACA3-366840CB2B10Q30551530-8E4144AC-9DBB-4A21-8B2C-B0DA1FEFBE8FQ33514871-BC6F9BF4-37D9-4CE0-A771-2243E784BA23Q33518799-DE16AE22-E714-4E34-840E-DDAF6C7628B7Q33585657-39DC50DD-11E8-4D4A-8612-DD4D4AAD96EDQ33639520-A30D2C1A-DE89-41FA-8CED-C90BAAD9A25FQ33849597-DF069819-A6CC-485A-83EE-E3A8EF8EEA2EQ33962601-F1CB00CC-D24B-4E17-BF4A-25FCAC2393FBQ34049297-C8DC7C42-8B30-4DE9-B901-0E453D11CF75Q34086707-7CE88304-5164-415D-B312-0E73F6B8ED56Q34165847-F9E4F911-4F7E-46B7-8397-E525DBF1A73EQ34299000-0E1DEC3F-7C42-426C-873F-4F9C4AD872A8Q34412608-ACE2B208-14BD-4412-907F-CF910A1702CCQ34482158-CE4B630B-5BA1-404E-BE23-FE022345A88DQ34492831-BC94ACEF-E8C9-48BD-813E-861F3BC34F5EQ34509964-C7768614-AA73-47DD-AEB7-2555B71578B6Q34586834-F1A0921F-8EB8-4B28-81B4-316DAF461E1FQ34591282-2D114A74-E435-4B29-94F6-7CAB449571C5Q34790065-17DE2ADF-C4D4-40D3-B4BB-6C19E6CCADB4Q34895911-CF277689-8630-46BE-B57E-4C0A1BFA2D2EQ34962291-2683EDCB-E1DD-4F8D-B541-5BE0D15E90FBQ34986368-485A9D54-07AC-4148-9645-B346FD07A6A5Q35144057-604A0373-B672-4B0B-AE24-3A8BB3F5E001Q35309535-99F5C510-A235-4AE7-B5D2-833460521665Q35588934-8D048C29-8FBB-48CE-AAA8-8F6A559EB3A8Q35636695-97B25E6F-E820-4ECD-8247-51DBC65A1266Q35794254-4A14FB8B-68FE-4A61-B889-E17B45404E84Q35925357-C25B66C5-C063-4A03-9C39-9B0A1E513842Q35925566-354780A4-1E03-4939-840A-C383CA71A98CQ36007212-E2FB39E8-962B-483C-90B4-9F8F62680E04Q36012843-F8534AC1-8231-4C3E-BF34-01D3ECCF0A92Q36018557-388B842B-2FF1-47A4-8F94-E82F312E8266Q36076407-C9BC6484-1054-4857-B340-B81F92B97F82Q36174974-5A65D60D-3941-40CD-9D89-B8F8224493AEQ36278716-7458B9B6-1584-4F50-A9D8-89E093B49D98Q36401585-C71AA198-8156-4556-AF4D-AEAC9A47EAA1Q36403404-682CEFC9-54FC-44A5-9B1F-D4C928C17023Q36405110-04209A1C-45C8-40C7-B5E8-0A9E1433D372Q36426782-5B173C33-0003-4F11-A64C-95F13FA3D651
P2860
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@ast
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@en
type
label
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@ast
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@en
prefLabel
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@ast
Troglitazone inhibits atherosc ...... ts on CD36 expression and HDL.
@en
P2093
P356
P1476
Troglitazone inhibits atherosc ...... cts on CD36 expression and HDL
@en
P2093
F Shionoiri
S Ishibashi
P304
P356
10.1161/01.ATV.21.3.372
P407
P50
P577
2001-03-01T00:00:00Z